Koji Haratani
Overview
Explore the profile of Koji Haratani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fujimoto D, Shibaki R, Kimura K, Haratani K, Tamiya M, Kijima T, et al.
Lung Cancer
. 2025 Jan;
199:108079.
PMID: 39787635
Objectives: The lack of definitive biomarkers presents a significant challenge for chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). We aimed to identify key genes associated with chemo-immunotherapy efficacy in ES-SCLC...
2.
Osaki T, Wan Z, Haratani K, Jin Y, Campisi M, Barbie D, et al.
bioRxiv
. 2024 Oct;
PMID: 39415995
Rett syndrome (RTT) is a neurodevelopmental disorder that is caused by mutations in melty-CpG binding protein 2 (MeCP2). MeCP2 is a non-cell type-specific DNA binding protein, and its mutation influences...
3.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, et al.
J Clin Invest
. 2024 Apr;
134(7).
PMID: 38557498
BACKGROUNDPrecise stratification of patients with non-small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy.METHODSWe measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4...
4.
Haratani K, Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, et al.
Br J Cancer
. 2024 Mar;
130(11):1783-1794.
PMID: 38519705
Background: Immune-related adverse events (irAEs) have been found to predict PD-L1 inhibitor efficacy in metastatic NSCLC. However, the relation of irAEs to clinical outcome for nonmetastatic NSCLC has remained unknown....
5.
Tani T, Mathsyaraja H, Campisi M, Li Z, Haratani K, Fahey C, et al.
Cancer Discov
. 2024 Jan;
14(5):752-765.
PMID: 38227896
Significance: STING-IFN signaling in cancer cells promotes tumor cell immunogenicity. Inactivation of the DNA exonuclease TREX1, which is adaptively upregulated to limit pathway activation in cancer cells, recruits immune effector...
6.
Masuda T, Miura S, Sato Y, Tachihara M, Bessho A, Nakamura A, et al.
Sci Rep
. 2023 Nov;
13(1):19729.
PMID: 37957228
Small amounts of epidermal growth factor receptor (EGFR) T790M mutation (micro-T790M), which is detected using droplet digital PCR (ddPCR) but not conventional PCR, in formalin-fixed and paraffin-embedded (FFPE) samples have...
7.
Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, et al.
Cancer Med
. 2023 Nov;
12(23):21097-21110.
PMID: 37948122
Background: Actionable tumor genomic alterations, primarily EGFR mutations, occur in nearly 70% of Japanese advanced nonsquamous non-small cell lung cancer (NSCLC) patients. Standard assessment of tumor tissue includes rapid testing...
8.
Gerton T, Green A, Campisi M, Chen M, Gjeci I, Mahadevan N, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627156
High-grade serous ovarian cancer (HGSOC) is responsible for the majority of gynecology cancer-related deaths. Patients in remission often relapse with more aggressive forms of disease within 2 years post-treatment. Alternative...
9.
Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, et al.
Oncol Lett
. 2023 Aug;
26(2):355.
PMID: 37545623
There have been few studies on predictive biomarkers that may be useful to select the most suitable opioids to optimize therapeutic efficacy in individual patients with cancer pain. We recently...
10.
Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, et al.
J Thorac Oncol
. 2023 Jun;
18(10):1334-1350.
PMID: 37364849
Introduction: The PACIFIC regimen of consolidation therapy with the programmed cell death-ligand 1 inhibitor durvalumab after definitive concurrent chemoradiation therapy has become a standard of care for individuals with unresectable...